End

Oportun Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Rate, ROE, Earnings per share, EPS, End, GAAP

Originations – Aggregate Originations for the first quarter were $338 million, a decrease of 17% as compared to $408 million in the prior-year quarter.

Key Points: 
  • Originations – Aggregate Originations for the first quarter were $338 million, a decrease of 17% as compared to $408 million in the prior-year quarter.
  • Revenue – Total revenue for the first quarter was $250 million, a decrease of 3% as compared to $260 million in the prior-year quarter.
  • Net Charge-Off Rate – The Annualized Net Charge-Off Rate for the quarter was 12.0%, compared to 12.1% for the prior-year quarter.
  • Oportun is providing the following guidance for 2Q 2024 and full year 2024 as follows:

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 5月 9, 2024
ENDO, Defecation, FDA, Holocene, Investment, CAH, Safety, NDA, Pharmacokinetics, Food, Carcinoid syndrome, Research, Acromegaly, Conference, Webcast, Congenital adrenal hyperplasia, Endocrine system, Therapy, Patient, Cushing's disease, SAN, End, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET Today
    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.
  • “Building on the positive momentum from the first PATHFNDR readout in 2023, Crinetics began 2024 with continued strong performance.
  • We plan to report initial results from a subset of patients from these trials in the second quarter,” continued Dr. Struthers.
  • In March, Crinetics reported positive topline results from its placebo-controlled Phase 3 study of paltusotine in non-pharmacologically treated participants with acromegaly.

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 5月 8, 2024
Vaccination, Public, Advisory Committee, Net, Ageing, Tolerability, Investment, PCV15, PCV, Safety, Phase 10, Infant, Infection, Trial of the century, Conference, Growth, Administration, Lonza, Immunization, Exercise, Research and development, Bank, ACIP, Stage 2, Initiate, PCV20, G&A, SAN, End, Genetically modified bacteria, IPD, Vaccine

SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) --  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • “We also continue to progress our early-stage pipeline led by VAX-A1, a vaccine candidate designed to prevent Group A Strep infections.
  • The aggregate gross proceeds to Vaxcyte from this offering were $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • The March 31, 2024 amount includes the $816.5 million in net proceeds from the follow-on offering completed in February 2024.
  • As of March 31, 2024, Vaxcyte had incurred $101.8 million in total capital and facility buildout expenditures that were reflected on the Company’s balance sheet as of that date.

BingX and WDC Made Progress in Ending Captivity of Whales and Dolphins

Retrieved on: 
火曜日, 4月 16, 2024
Summer, Social media, Travel, Breeding, Jet2holidays, WDC, Partnership, Research, Whale, Dolphin, Royal assent, End, Whaling

The project targets the burgeoning industry of cetacean captivity, which currently sees more than 3,600 whales and dolphins confined in 350 facilities across 59 countries, primarily in coastal regions.

Key Points: 
  • The project targets the burgeoning industry of cetacean captivity, which currently sees more than 3,600 whales and dolphins confined in 350 facilities across 59 countries, primarily in coastal regions.
  • Vivien Lin, Spokesperson for BingX, expressed enthusiasm for the progress: "The values of BingX and WDC strongly align in our shared passion to protect whales and dolphins.
  • We've made remarkable progress through the End Captivity Project, advancing vital research and raising awareness about the harsh realities of captivity.
  • Following the recent success, WDC and BingX are gearing up for the Summer Captivity Campaign, targeting high-profile dolphinaria in European resorts.

Lands’ End Announces Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on: 
水曜日, 3月 27, 2024
Growth, End, International, Capital expenditure, Third party, Inventory, Share repurchase, Fiscal, Delta Air Lines, Video game

DODGEVILLE, Wis., March 27, 2024 (GLOBE NEWSWIRE) -- Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the fourth quarter and full year of the fiscal year ended February 2, 2024. The Company also provided the first quarter and full year fiscal 2024 outlook.

Key Points: 
  • Excluding Lands’ End Japan in the fourth quarter of fiscal 2022, Global eCommerce net revenue decreased 0.6%.
  • Compared to fourth quarter of fiscal 2022, which included the results of Lands’ End Japan, International eCommerce Net revenue decreased 20.2%.
  • Outfitters Net revenue was $53.7 million for fourth quarter of fiscal 2023, a decrease of $6.8 million or 11.3% from $60.5 million during the fourth quarter of fiscal 2022.
  • Adjusted EBITDA was $31.7 million in the fourth quarter of fiscal 2023 compared to $24.2 million in the fourth quarter of fiscal 2022.

Virtual Internet Announces Virtual 5G Service Provider Control

Retrieved on: 
月曜日, 4月 8, 2024
Cloud, Telephone, Speedtest.net, Primary, EV, Worldwide, End user, Mobile phone, Memory, Risk, Accounting, SAN, Frequency, Location, Internet, Data, Tablet, Health care, Radio access network, GPS, Communication, Life, IP address, Reliability, City, Service, Data-rate units, End, Investment, Service provider, RAN, Central processing unit, Secondary, Android

Virtual 5G --The Global 5G Cloud

Key Points: 
  • SINGAPORE and SAN JOSE, Calif., April 8, 2024 /PRNewswire/ -- Virtual Internet has announced Virtual 5G Service Provider Control, enabling V5G Users with the insight to manage the Service Provider and Device selections.
  • Virtual 5G uniquely delivers Global 5G service over any service provider network, even when the underlying Service Provider connection is not 5G, to End User devices that are also not 5G.
  • Virtual 5G Service Provider Control enables gathering Android hardware data and valuable insights into your device's operations, enabling Virtual 5G users to make selections that troubleshoot service provider issues and optimize performance.
  • Virtual 5G and Virtual 5G Service Provider Control can be the difference in successfully reaching charging resources in time.

Lands' End Announces $25 Million Share Repurchase Authorization

Retrieved on: 
金曜日, 3月 15, 2024
Share repurchase, Hand, End, Security (finance)

The Company’s prior share repurchase authorization pursuant to which 2.3 million shares were repurchased for an aggregate $20.3 million beginning in June 2022, expired on February 2, 2024.

Key Points: 
  • The Company’s prior share repurchase authorization pursuant to which 2.3 million shares were repurchased for an aggregate $20.3 million beginning in June 2022, expired on February 2, 2024.
  • All repurchases will be subject to compliance with the Company’s Term Loan credit agreement which imposes a per fiscal year limitation on share repurchases.
  • Bernard McCracken, Chief Financial Officer, said, “This new share repurchase authorization demonstrates the Board and management team’s confidence in Lands’ End’s strategy and commitment to shareholder value creation.
  • The share repurchase program may be suspended or discontinued at any time.

Oportun Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
火曜日, 3月 12, 2024
Growth, Rate, EPS, ROE, Acquisition, Sale, Principal balance, Adjustment, End, GAAP, Earnings, Marketing

Originations – Aggregate Originations for the fourth quarter were $437 million, a decrease of 28% as compared to $610 million in the prior-year quarter.

Key Points: 
  • Originations – Aggregate Originations for the fourth quarter were $437 million, a decrease of 28% as compared to $610 million in the prior-year quarter.
  • Portfolio Yield – Portfolio Yield as of the end of fourth quarter was 32.7%, an increase of 100 basis points as compared to 31.7% in the prior-year quarter.
  • Revenue – Total revenue for the fourth quarter was $263 million, essentially flat as compared to total revenue of $262 million in the prior-year quarter.
  • Cost of Debt was 7.1% for the fourth quarter of 2023 as compared to 4.8% for the prior-year quarter.

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 2月 27, 2024
Licensure, Investment, Growth, Exercise, Tolerability, Immunization, Host, Trial of the century, Ageing, PCV20, PCV, P-value, Safety, BLA, Success, Phase 10, Genetically modified bacteria, Net, G&A, CMC, SAN, Research and development, ID, OPA, Conference, The Lancet, Biologics license application, Breakthrough therapy, Advisory Committee, PCV15, POC, FDA, End, Food, Breakthrough, Element, Fireside chats, Administration, IPD

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Retrieved on: 
木曜日, 1月 4, 2024
Licensure, Food, PCV, End, Breakthrough therapy, FDA, CMC, Ageing, Phase 10, SAN, Pivotal, Biologics license application, Advisory Committee, PCV20, Breakthrough, Data monitoring committee, Immunization, Initiation, IPD, PCV15, Infant, Safety, Tolerability, Genetically modified bacteria, BLA, Vaccine

-- Enrollment in Ongoing VAX-24 Infant Phase 2 Study Continues to Progress; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 --

Key Points: 
  • Vaxcyte’s carrier-sparing PCV franchise candidates, including VAX-24, a 24-valent PCV proceeding to Phase 3, and VAX-31, the Company’s next-generation 31-valent PCV, are being studied for the prevention of invasive pneumococcal disease (IPD).
  • The VAX-24 Phase 2 infant study continues to enroll participants in the second and final stage of the study.
  • This is a randomized, observer-blind, dose-finding two-stage clinical study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy infants.
  • Topline safety, tolerability and immunogenicity data from the ongoing adult Phase 1/2 study in the third quarter of 2024.